<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945448</url>
  </required_header>
  <id_info>
    <org_study_id>ST/225/2018</org_study_id>
    <nct_id>NCT03945448</nct_id>
  </id_info>
  <brief_title>Single Dose Liposomal Amphotericin for Asymptomatic Cryptococcal Antigenemia</brief_title>
  <acronym>ACACIA</acronym>
  <official_title>Evaluation of CrAg Screening With Enhanced Antifungal Therapy for Asymptomatic CrAg+ Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg
      positive persons in Uganda.

      Patients will be randomized to receive preemptive treatment with 1 dose of liposomal
      amphotericin (10mg/kg) in addition to standard of care fluconazole therapy.

      How the enhanced antifungal therapy prevents progression to meningitis in the first 24-weeks
      and overall survival in those who receive the intervention compared with participants
      receiving fluconazole per World Health Organisation (WHO) and national standard of care
      therapy will be evaluated.

      Survival will also be evaluated by CrAg titer (comparing high titers who received Liposomal
      Amphotericin B (L-AMB) to high titers who received fluconazole alone), safety, tolerability,
      and cost-effectiveness of this regimen.

      600 patients will be enrolled,300 in each arm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that develop meningitis in the AMBISOME arm compared to the fluconazole arm.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Comparison will be made between those randomized to single dose liposomal amphotericin + standard of care (fluconazole) vs. standard of care (fluconazole) alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of grade 3 to 5 clinical adverse events or serious adverse events</measure>
    <time_frame>within two weeks of enrollment</time_frame>
    <description>Symptoms causing inability to perform social and functional activities and potentially life threatening symptoms requiring intervention or hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of grade 3 to 5 laboratory adverse events by NIAID DAIDS toxicity scale</measure>
    <time_frame>within two weeks of enrollment</time_frame>
    <description>Abnormal laboratory findings that meet the DAIDS categorization of grade 3 and 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness of single dose liposomal amphotericin + fluconazole compared to fluconazole preemptive therapy alone, and compared to no preemptive therapy.</measure>
    <time_frame>24 weeks</time_frame>
    <description>what will be the added cost required to treat patients with AMBISOME when assessed in light of the outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients that will survive in the 24-week period.</measure>
    <time_frame>24 weeks</time_frame>
    <description>How many patients will be alive at 24 weeks when the two arms are compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Cryptococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>Single dose liposomal Amphotericin and fluconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental:
Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fluconazole (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose liposomal Amphotericin and Fluconazole</intervention_name>
    <description>Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.</description>
    <arm_group_label>Single dose liposomal Amphotericin and fluconazole</arm_group_label>
    <other_name>AMBISOME and fluconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months</description>
    <arm_group_label>fluconazole (standard of care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  Age &gt;18 years

          -  Ability and willingness to give informed consent.

          -  Plasma/Serum cryptococcal antigen (CRAG)+

        Exclusion Criteria:

          -  Cannot or unlikely to attend regular clinic visits

          -  History of cryptococcal infection

          -  Symptomatic meningitis (confirmed by CSF CRAG+)

          -  &gt;14 days of fluconazole therapy

          -  Pregnancy (confirmed by urinary or serum pregnancy test)

          -  Current breastfeeding

          -  Known allergy to amphotericin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>DAVID MEYA, PhD</last_name>
    <phone>+256 772 543 730</phone>
    <email>david.meya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ELIZABETH NALINTYA, MPH</last_name>
    <phone>+256 771 321 617</phone>
    <email>enalintya@idi.co.ug</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>infectious Disease Institute Kampala,Uganda</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAVID MEYA, PhD</last_name>
      <phone>+256 772 543 730</phone>
      <email>david.meya@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ELIZABETH NALINTYA, MPH</last_name>
      <phone>+256 771 321 617</phone>
      <email>enalintya@idi.co.ug</email>
    </contact_backup>
    <investigator>
      <last_name>DAVID MEYA, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Cryptococcal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Amphotericin B</mesh_term>
    <mesh_term>Liposomal amphotericin B</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT03945448/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

